Evidence map›Paper›PMID 25453977›Full record

ArticleBiomaterials2015

Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers.

Martina Miteva, Kellye C Kirkbride, Kameron V Kilchrist, Thomas A Werfel, Hongmei Li, Christopher E Nelson, Mukesh K Gupta, Todd D Giorgio, Craig L Duvall

Abstract read
In one paragraph

Article in Biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. CRISPR/Cas9 Delivery Systems to Enhance Gene Editing Efficiency.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Martina MitevaBiomedical Engineering, Vanderbilt University, VU Station B 351631, Nashville, TN 37235-1631, USA.
Kellye C KirkbrideBiomedical Engineering, Vanderbilt University, VU Station B 351631, Nashville, TN 37235-1631, USA.
Kameron V KilchristBiomedical Engineering, Vanderbilt University, VU Station B 351631, Nashville, TN 37235-1631, USA.
Thomas A WerfelBiomedical Engineering, Vanderbilt University, VU Station B 351631, Nashville, TN 37235-1631, USA.
Hongmei LiBiomedical Engineering, Vanderbilt University, VU Station B 351631, Nashville, TN 37235-1631, USA.
Christopher E NelsonBiomedical Engineering, Vanderbilt University, VU Station B 351631, Nashville, TN 37235-1631, USA.
Mukesh K GuptaBiomedical Engineering, Vanderbilt University, VU Station B 351631, Nashville, TN 37235-1631, USA.
Todd D GiorgioBiomedical Engineering, Vanderbilt University, VU Station B 351631, Nashville, TN 37235-1631, USA.
Craig L DuvallBiomedical Engineering, Vanderbilt University, VU Station B 351631, Nashville, TN 37235-1631, USA. Electronic address: craig.duvall@vanderbilt.edu.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
TRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI POWERS, ALVIN C · 1986 to 2011
$28.1M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
THREE-TIERED PREVENTION MODEL TO BETTER SERVE ALL STUDENP30HD015052 · NICHD · VANDERBILT UNIVERSITY · PI HARRELL, FRANK E. · 1985 to 2014
$18.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Vanderbilt Mouse Metabolic Phenotyping CenterU2CDK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2016 to 2021
$6.3M
Injectable Scaffold for Efficient, Tunable siRNA Delivery to Skin WoundsR21EB012750 · NIBIB · VANDERBILT UNIVERSITY · PI DUVALL, CRAIG LEWIS · 2011 to 2012
$418k
NCI NIH HHS CA68485NCI NIH HHS P30 CA068485NEI NIH HHS EY08126NEI NIH HHS P30 EY008126NIBIB NIH HHS R21 EB012750NICHD NIH HHS HD15052NICHD NIH HHS P30 HD015052NIDDK NIH HHS DK20593NIDDK NIH HHS DK58404NIDDK NIH HHS DK59637NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS P60 DK020593NIDDK NIH HHS U24 DK059637
6 · The paper itself

Abstract

A series of endosomolytic mixed micelles was synthesized from two diblock polymers, poly[ethylene glycol-b-(dimethylaminoethyl methacrylate-co-propylacrylic acid-co-butyl methacrylate)] (PEG-b-pDPB) and poly[dimethylaminoethyl methacrylate-b-(dimethylaminoethyl methacrylate-co-propylacrylic acid-co-butyl methacrylate)] (pD-b-pDPB), and used to determine the impact of both surface PEG density and PEG molecular weight on overcoming both intracellular and systemic siRNA delivery barriers. As expected, the percent PEG composition and PEG molecular weight in the corona had an inverse relationship with mixed micelle zeta potential and rate of cellular internalization. Although mixed micelles were internalized more slowly, they generally produced similar gene silencing bioactivity (∼ 80% or greater) in MDA-MB-231 breast cancer cells as the micelles containing no PEG (100 D/no PEG). The mechanistic explanation for the potent bioactivity of the promising 50 mol% PEG-b-DPB/50 mol% pD-b-pDPB (50 D) mixed micelle formulation, despite its relatively low rate of cellular internalization, was further investigated as a function of PEG molecular weight (5 k, 10 k, or 20 k PEG). Results indicated that, although larger molecular weight PEG decreased cellular internalization, it improved cytoplasmic bioavailability due to increased intracellular unpackaging (quantitatively measured via FRET) and endosomal release. When delivered intravenously in vivo, 50 D mixed micelles with a larger molecular weight PEG in the corona also demonstrated significantly improved blood circulation half-life (17.8 min for 20 k PEG micelles vs. 4.6 min for 5 kDa PEG micelles) and a 4-fold decrease in lung accumulation. These studies provide new mechanistic insights into the functional effects of mixed micelle-based approaches to nanocarrier surface PEGylation. Furthermore, the ideal mixed micelle formulation identified (50 D/20 k PEG) demonstrated desirable intracellular and systemic pharmacokinetics and thus has strong potential for in vivo therapeutic use.

Indexed as

AnimalsDiffusionDrug CompoundingHumansMethacrylatesMiceMice, Inbred BALB CMicellesNanocapsulesParticle SizePolyethylene GlycolsRNA, Small InterferingSubcellular Fractionsbutyl methacrylateMethacrylatesMicellesNanocapsulesPolyethylene GlycolsRNA, Small InterferingFRET imagingIntracellular drug releaseMixed micellesNanoparticle PEGylationPharmacokineticssiRNA

Identifiers

PMID25453977
PMCPMC5477977

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.